99 related articles for article (PubMed ID: 25226352)
1. Camptothecin Enhances Cell Death Induced by (177)Lu-EDTMP in Osteosarcoma Cells.
Kumar C; Vats K; Lohar SP; Korde A; Samuel G
Cancer Biother Radiopharm; 2014 Oct; 29(8):317-22. PubMed ID: 25226352
[TBL] [Abstract][Full Text] [Related]
2. Relaxin inhibits
Xu J; Wan S; Chen W; Zhang Y; Ji Z
Acta Pharm; 2022 Dec; 72(4):575-585. PubMed ID: 36651368
[No Abstract] [Full Text] [Related]
3. Cellular toxicity and apoptosis studies in osteocarcinoma cells, a comparison of 177Lu-EDTMP and Lu-EDTMP.
Kumar C; Korde A; Kumari KV; Das T; Samuel G
Curr Radiopharm; 2013 Sep; 6(3):146-51. PubMed ID: 23895775
[TBL] [Abstract][Full Text] [Related]
4. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
Das T; Sarma HD; Shinto A; Kamaleshwaran KK; Banerjee S
Cancer Biother Radiopharm; 2014 Dec; 29(10):412-21. PubMed ID: 25409337
[TBL] [Abstract][Full Text] [Related]
5.
Kumar C; Sharma R; Das T; Korde A; Sarma H; Banerjee S; Dash A
J Labelled Comp Radiopharm; 2018 Sep; 61(11):837-846. PubMed ID: 29923620
[TBL] [Abstract][Full Text] [Related]
6. Timing and optimized acquisition parameters for the whole-body imaging of ¹⁷⁷Lu-EDTMP toward performing bone pain palliation treatment.
Liu C; Brašić JR; Liu X; Li H; Xiang X; Luo Z; Wang Y; Kuai D; Zhang G; Zaknun JJ
Nucl Med Commun; 2012 Jan; 33(1):90-6. PubMed ID: 22001721
[TBL] [Abstract][Full Text] [Related]
7. Comparative studies on the potential use of
Zakaly HMH; Mostafa MYA; Deryabina D; Zhukovsky M
Int J Radiat Biol; 2020 Jun; 96(6):779-789. PubMed ID: 32043915
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.
Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ
Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120
[TBL] [Abstract][Full Text] [Related]
9. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma.
Franzius C; Bielack S; Flege S; Eckardt J; Sciuk J; Jürgens H; Schober O
Nuklearmedizin; 2001 Dec; 40(6):215-20. PubMed ID: 11797510
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis.
Chakraborty S; Das T; Sarma HD; Venkatesh M; Banerjee S
Appl Radiat Isot; 2008 Sep; 66(9):1196-205. PubMed ID: 18372188
[TBL] [Abstract][Full Text] [Related]
11. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent.
Máthé D; Balogh L; Polyák A; Király R; Márián T; Pawlak D; Zaknun JJ; Pillai MR; Jánoki GA
Nucl Med Biol; 2010 Feb; 37(2):215-26. PubMed ID: 20152721
[TBL] [Abstract][Full Text] [Related]
12. 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients.
Berger M; Grignani G; Giostra A; Ferrari S; Ferraresi V; Tamburini A; Cefalo G; Carnevale-Schianca F; Vassallo E; Picci P; Pagano M; Aglietta M; Pellerito RE; Fagioli F
Ann Oncol; 2012 Jul; 23(7):1899-905. PubMed ID: 22104576
[TBL] [Abstract][Full Text] [Related]
13. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223.
Anderson PM; Subbiah V; Rohren E
Adv Exp Med Biol; 2014; 804():291-304. PubMed ID: 24924181
[TBL] [Abstract][Full Text] [Related]
14. ¹⁷⁷Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases.
Shinto AS; Shibu D; Kamaleshwaran KK; Das T; Chakraborty S; Banerjee S; Thirumalaisamy P; Das P; Veersekar G
J Nucl Med Technol; 2014 Mar; 42(1):55-61. PubMed ID: 24503346
[TBL] [Abstract][Full Text] [Related]
15.
Askari E; Harsini S; Vahidfar N; Divband G; Sadeghi R
Cancer Biother Radiopharm; 2021 Jun; 36(5):383-390. PubMed ID: 33259726
[No Abstract] [Full Text] [Related]
16. Evaluation of ¹⁷⁷Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy.
Chakraborty S; Balogh L; Das T; Polyák A; Andócs G; Máthé D; Király R; Thuróczy J; Chaudhari PR; Jánoki GA; Jánoki G; Banerjee S; Pillai MR
Curr Radiopharm; 2016; 9(1):64-70. PubMed ID: 25771374
[TBL] [Abstract][Full Text] [Related]
17. Comparison of systemic toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs.
Bryan JN; Bommarito D; Kim DY; Berent LM; Bryan ME; Lattimer JC; Henry CJ; Engelbrecht H; Ketring A; Cutler C
J Nucl Med Technol; 2009 Mar; 37(1):45-52. PubMed ID: 19223431
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib.
Nonnekens J; van Kranenburg M; Beerens CE; Suker M; Doukas M; van Eijck CH; de Jong M; van Gent DC
Theranostics; 2016; 6(11):1821-32. PubMed ID: 27570553
[TBL] [Abstract][Full Text] [Related]
19. Intraorgan biodistribution and dosimetry of 153Sm-ethylenediaminetetramethylene phosphonate in juvenile rabbit tibia: implications for targeted radiotherapy of osteosarcoma.
Essman SC; Lewis MR; Miller WH
J Nucl Med; 2005 Dec; 46(12):2076-82. PubMed ID: 16330573
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
